Brokerages Set Eton Pharmaceuticals, Inc. (NASDAQ:ETON) PT at $39.33

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has received a consensus rating of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $39.3333.

ETON has been the topic of a number of recent analyst reports. Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. HC Wainwright increased their price objective on shares of Eton Pharmaceuticals from $37.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Wall Street Zen raised shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd.

Eton Pharmaceuticals Price Performance

Shares of ETON opened at $26.40 on Thursday. Eton Pharmaceuticals has a fifty-two week low of $11.09 and a fifty-two week high of $26.81. The firm’s 50 day moving average price is $19.09 and its 200 day moving average price is $17.98. The company has a market cap of $720.19 million, a P/E ratio of -146.66 and a beta of 0.97. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.83.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, March 19th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). Eton Pharmaceuticals had a negative net margin of 5.75% and a negative return on equity of 2.60%. The firm had revenue of $21.28 million during the quarter, compared to analysts’ expectations of $20.58 million. On average, research analysts forecast that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of large investors have recently modified their holdings of the company. State of Alaska Department of Revenue purchased a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at $30,000. Ameritas Investment Partners Inc. purchased a new position in shares of Eton Pharmaceuticals in the 2nd quarter valued at $37,000. Quarry LP acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth $37,000. Legal & General Group Plc acquired a new stake in Eton Pharmaceuticals during the 2nd quarter worth $41,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth $44,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.